Celcuity Prices Public Offering of $248.7mln, Raises $175mln in 2.75% Sr. Notes and $1.84mln in Shares.
PorAinvest
miércoles, 30 de julio de 2025, 7:23 am ET1 min de lectura
CELC--
The convertible senior notes carry an interest rate of 2.75% and will mature on August 1, 2031, unless converted, redeemed, or repurchased by the company. The notes are unsecured and senior obligations of the company, with interest payable semi-annually in arrears. The company plans to use the net proceeds from these offerings to fund clinical trials, commercial launch expenditures, research and development, and other general corporate purposes.
The stock offering is expected to close on July 31, while the notes offering is set to close on August 1. Jefferies, TD Cowen, and Leerink Partners are acting as joint book-running managers for both offerings, with LifeSci Capital serving as the lead manager for the notes offering and a passive bookrunner for the stock offering.
The company has filed registration statements with the Securities and Exchange Commission (SEC) for both offerings, including preliminary prospectus supplements. Investors are advised to review these documents for complete information about the company and these offerings. The documents can be obtained by visiting EDGAR on the SEC’s website at www.sec.gov or by contacting the company, underwriters, or dealers participating in the offerings.
Reference List:
[1] https://www.morningstar.com/news/globe-newswire/9501739/celcuity-inc-announces-concurrent-public-offerings-of-convertible-senior-notes-due-2031-and-common-stock
Celcuity has priced a public offering of $175mln 2.75% convertible senior notes due 2031 and sold 1.84mln shares at $38/shr. The company plans to use the proceeds for working capital and general corporate purposes. The notes offering is expected to close on August 1, while the stock offering is expected to close on July 31.
Minneapolis, July 2, 2025 — Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company focused on developing targeted therapies for oncology, has successfully priced a public offering of $175 million in convertible senior notes due 2031. The company also sold 1.84 million shares of common stock at $38 per share, raising $69.92 million. The proceeds from these offerings will be used for working capital and general corporate purposes.The convertible senior notes carry an interest rate of 2.75% and will mature on August 1, 2031, unless converted, redeemed, or repurchased by the company. The notes are unsecured and senior obligations of the company, with interest payable semi-annually in arrears. The company plans to use the net proceeds from these offerings to fund clinical trials, commercial launch expenditures, research and development, and other general corporate purposes.
The stock offering is expected to close on July 31, while the notes offering is set to close on August 1. Jefferies, TD Cowen, and Leerink Partners are acting as joint book-running managers for both offerings, with LifeSci Capital serving as the lead manager for the notes offering and a passive bookrunner for the stock offering.
The company has filed registration statements with the Securities and Exchange Commission (SEC) for both offerings, including preliminary prospectus supplements. Investors are advised to review these documents for complete information about the company and these offerings. The documents can be obtained by visiting EDGAR on the SEC’s website at www.sec.gov or by contacting the company, underwriters, or dealers participating in the offerings.
Reference List:
[1] https://www.morningstar.com/news/globe-newswire/9501739/celcuity-inc-announces-concurrent-public-offerings-of-convertible-senior-notes-due-2031-and-common-stock

Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema

Comentarios
Aún no hay comentarios